A phase I study by Pullarkat et al. used venetoclax (selective BCL2 inhibitor), with low-dose navitoclax, a BCL-XL/BCL2 inhibitor, in combination with chemotherapy in relapsed/refractory ALL patients, and reported promising outcomes within all genomic subtypes, although in Ph-like and Ph-positive ALL, responses were fewer. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.